Regeneron

News

Lilly's antibody therapy cuts hospitalisation rates in COVID...

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease.<

News

Regeneron tests COVID-19 antibody therapy in UK's RECOVERY t...

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the

News

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19.

News

Regeneron recruits Roche to make COVID-19 antibody drug REGN...

Roche has agreed to help Regeneron manufacture its COVID-19 antibody cocktail REGN-COV2, which started late-stage clinical testing a few weeks ago, in a deal that could more th

News

Regeneron’s cholesterol drug evinacumab claims February FDA ...

The FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease.<

News

Regeneron pairs with BioNTech on melanoma immunotherapy

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other ch

Lilly's antibody therapy cuts hospitalisation rates in COVID...

Regeneron tests COVID-19 antibody therapy in UK's RECOVERY t...

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Regeneron recruits Roche to make COVID-19 antibody drug REGN...

Regeneron’s cholesterol drug evinacumab claims February FDA ...

Regeneron pairs with BioNTech on melanoma immunotherapy

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Regeneron

Editor's Picks